Skip to content
10-K

Annual Report

REGEN BIOPHARMA, INC. RGBP RGBPP

0001493152-25-029526

← back to feed
Filed
Dec 30, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Dec 26, 2025 108.05M sh
Shares Diluted FY 2025 · Sep 30, 2025 23.52M sh
Shares Diluted FY 2025 · Sep 30, 2024 4.11M sh
Operating Cash Flow FY 2025 · Sep 30, 2025 −$383.59K
Operating Cash Flow FY 2025 · Sep 30, 2024 −$751.54K
Cash And Equivalents FY 2025 · Sep 30, 2025 $69.56K
Cash And Equivalents FY 2025 · Sep 30, 2024 $716
Stockholders Equity FY 2025 · Sep 30, 2025 −$6.28M
Stockholders Equity FY 2025 · Sep 30, 2024 −$5.22M
Stockholders Equity restated FY 2025 · Sep 30, 2023 −$5.1M
Current Liabilities FY 2025 · Sep 30, 2025 $6.56M
Current Liabilities restated FY 2025 · Sep 30, 2024 $5.38M
Total Liabilities FY 2025 · Sep 30, 2025 $6.56M
Total Liabilities restated FY 2025 · Sep 30, 2024 $5.38M
Current Assets FY 2025 · Sep 30, 2025 $274.63K
Current Assets FY 2025 · Sep 30, 2024 $143.35K
Total Assets FY 2025 · Sep 30, 2025 $274.63K
Total Assets FY 2025 · Sep 30, 2024 $161.08K
Eps Diluted FY 2025 · Sep 30, 2025 −$0.05
Eps Diluted FY 2025 · Sep 30, 2024 −$0.16
Eps Basic FY 2025 · Sep 30, 2025 −$0.05
Eps Basic FY 2025 · Sep 30, 2024 −$0.16
Rd Expense FY 2025 · Sep 30, 2025 $11.73K
Rd Expense FY 2025 · Sep 30, 2024 $153.69K
Net Income FY 2025 · Sep 30, 2025 −$1.27M
Net Income FY 2025 · Sep 30, 2024 −$668.26K
Operating Income FY 2025 · Sep 30, 2025 −$338.54K
Operating Income FY 2025 · Sep 30, 2024 −$417.22K
Revenue FY 2025 · Sep 30, 2025 $236.56K
Revenue FY 2025 · Sep 30, 2024 $236.56K